Complex study requirements and a lack of validated biomarkers make this crowded research space a logistical minefield. Worldwide offers breakthrough solutions to make this intractable indication less painful to study
Worldwide is a leader in best practice development for pain research. Our physicians and scientists understand the specific therapeutic and methodological challenges in analgesic research, which helps us offer creative study designs and thoughtful protection of outcome measures coupled with operational expertise.
Vice President, Neuroscience, Scientific Solutions
Christine Moore, Ph.D., is an experimental psychologist by training with expertise in clinical trial methodology, particularly in analgesia. With over 25 years of drug development experience, her expertise extends to diverse roles operationally and through commercialization at CROs and with large and small pharma. She has designed and written numerous protocols for breakthrough cancer pain, osteoarthritis, chronic low back pain, acute pain models (bunionectomy, hip/knee replacement, dental pain), neuropathic pain (diabetic neuropathy, fibromyalgia), and migraine, as well as formulated pre-launch and post-marketing publication plans. She has also provided training for minimizing placebo response for multiple individual pain trials. Dr. Moore’s unique and broad experience across a variety of roles in the industry in analgesia allows for planning of registration trials that are feasible and that will enable commercial product adoption by payers and health care providers after approval.
In pain research, rigorous attention to the details is incredibly important—but so is the practical translation of those details to a big-picture solution. Worldwide—the cure for the common CRO—embraces this complexity and connectivity.
Worldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.
Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a dizzying number of compounds and indications in every phase. Now Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services in addition to our top-notch global network of study execution experts.
Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.
Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.
A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.
We’ve been a part of industry-sponsored psychedelic trials since they began. Our Psychedelic Center of Excellence has a comprehensive approach to the complex operational delivery of these trials and working with patients and sites for study success.